View Past PerformanceExpert.ai バランスシートの健全性財務の健全性 基準チェック /46Expert.aiの総株主資本は€25.1M 、総負債は€16.4Mで、負債比率は65.4%となります。総資産と総負債はそれぞれ€67.4Mと€42.3Mです。主要情報65.38%負債資本比率€16.42m負債インタレスト・カバレッジ・レシオn/a現金€13.60mエクイティ€25.12m負債合計€42.26m総資産€67.38m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 30+ 1 more updateExpert.ai S.p.A. to Report First Half, 2026 Results on Sep 28, 2026Expert.ai S.p.A. announced that they will report first half, 2026 results on Sep 28, 2026お知らせ • Nov 26Expert.ai Presents EIX-Customer Screening for Intelligent Adverse News Monitoring in the Financial SectorExpert.ai released its enhanced solution for helping banks and financial institutions continuously monitor and analyze media coverage related to potential criminal activity or investigations involving customers. Available through the EidenAI Suite, Expert.ai's ecosystem of AI tools and solutions designed for industry, EIX-Customer Screening leverages advanced technologies to reinforce anti-money laundering (AML) programs and help organizations adopt a more proactive Know Your Customer (KYC) approach. With financial crime on the rise and regulatory requirements becoming increasingly stringent, EIX- Customer Screening automates the monitoring and analysis of news related to customers and counterparties--in real time and on a global scale. The solution significantly reduces false positives, streamlines oversight activities and improves operational efficiency. Powered by a Hybrid AI approach that combines cutting-edge capabilities, EIX-Customer Screened processes large volumes of multilingual news and unstructured data to help teams quickly detect critical events and adverse media, such as criminal activity, investigations or legal proceedings while drastically reducing false positives. The solution also supports sanctions screening and identification of politically exposed persons (PEPs), enhancing compliance and due diligence workflows for better accuracy and security. EIX-Customer Screening sets a new standard for AML and KYC programs. Built on Expert.ai's extensive technological expertise, deep domain knowledge and years of experience serving leading banking and financial organizations, the solution offers enhanced support for analysts by enabling: Continuous monitoring and analysis of global information flows (news, corporate records, regulatory lists, etc.) to deliver a complete, 360deg view of customer risk; Intelligent detection and classification across 60+ crime categories; Extraction of contextual data (e.g., age, role, location of individuals involved); Customizable relevance and risk scoring with up to 90% reduction in false positives, enabling teams to focus on true risks and accelerate AML investigations and customer onboarding; Screening against major global sanctions lists (UN, EU, OFAC, etc.) and PEP Checks and automatic generation of reports, alerts and summaries for AML/KYC teams. EIX-Customer Screened supports both large institutions and small organizations, making it easy to scale monitoring across the entire customer portfolio or targeted segments. The solution is available and integrates seamlessly with leading compliance platforms.お知らせ • Oct 15Expert.ai Strengthens Its Offering for the Insurance Industry with Advanced AI SolutionsExpert.ai announced significant enhancements to its insurance solutions available through the EidenAI Suite. The updates further strengthen Expert.ai's position as the trusted AI partner for insurers, MGAs, brokers and TPAs, delivering measurable value across core insurance functions and helping organizations accelerate processes, reduce risk and enable scalability across operations. The improved offering includes three specialized solutions that deliver measurable value across core insurance functions. All are available as turnkey and highly customized deployments with built-in governance and monitoring capabilities to ensure safe, transparent and compliant adoption of AI: AI-Powered Underwriting: Accuracy and speed in underwriting are essential for competitive advantage. EIX-Underwriting leverages its proven Hybrid AI approach to streamline data extraction from unstructured documents and risk evaluation, ensuring scalable performance even during peak demand periods. All commercial lines, both admitted and E&S, are supported. Claims Automation: Designed to eliminate bottlenecks in high-volume, document-intensive claims environments, Expert.ai's EIX-Claims Automation solution intelligently classifies and extracts critical data from incoming documents, speeding resolutions, reducing leakage, and improving customer satisfaction. The solution includes legal demand identification and medical summarization. Policy Servicing Automation: Outdated servicing processes often slow operations and create low customer satisfaction. Through EIX-Policy Servicing, Expert.ai helps teams automate workflows, such as endorsement, audit and renewal processing, end-to-end, while enhancing compliance, reducing operational costs and improving service delivery with intelligent, auditable processes.お知らせ • Oct 07Expert.ai Introduces New AI Solutions to Accelerate Pharma & Life Sciences InnovationExpert.ai announced the debut of its new AI-powered offerings designed to accelerate innovation across the pharmaceutical, healthcare and life sciences industries. Launched at BioTechX Europe 2025, Europe's largest congress dedicated to pharma & healthcare, the new solutions enable organizations to enhance data analysis, streamline discovery processes and unlock new possibilities for clinical trials and therapeutic improvement: EIX-Submission Readiness empowers teams to build smarter, more efficient workflows for regulatory documentation. EIX-Preclinical Document Intelligence streamlines preclinical documentation with greater speed and accuracy, free experts to focus on innovation. EIX-Clinical Trials Intelligence helps research teams to distill the most accurate, up-to-date information by disrupting across mountains of content from clinical registries, scientific publications and real-world data. EIX-IP Detection delivers comprehensive, explainable insights across patents, scientific literature and clinical trial data. Leveraging its deep domain expertise and unique hybrid AI approach, Expert.ai helps researchers transform the complexity of research & development into strategic advantage. By reducing manual effort and scaling insights from massive volumes of data, the new solutions use the most effective AI techniques to ensure regulatory accuracy, improve trial design, accelerate patient recruitment, reduce costs and minimize the constant risks of delays. With these innovations, Expert.ai continues to set the standard for applying AI in Pharma & Life Sciences, delivering greater efficiency and reliability across the life sciences value chain through intelligent document automation and AI agents.お知らせ • Sep 12Expert.Ai Launches Enhanced Solutions for Digital Information ServicesExpert.ai presents enhanced AI-powered solutions purpose-built for Digital Information Services. In data-saturated landscape, information services organizations must quickly convert vast, diverse streams of both structured and unstructured information into clear, actionable insights. Expert.ai empowers this transformation through advanced Hybrid AI capabilities that automate classification, entity and relationship extraction, tagging and semantic enrichment, similarity detection, and personalized recommendations. By extending content usability, Expert.ai maximizes the value of data, simplifying its governance and supporting continuous innovation through the best of diverse AI techniques -- including neuro-symbolic AI, AI agents, LLMs and the broader Generative AI ecosystem -- all tailored to extract meaning from complexity. Transforming how information services teams operate, Expert.ai streamlines workflows, enabling professionals to focus on high-value tasks, accelerate insight generation and repurpose knowledge across domains. New Expert.ai solutions for Digital Information Services include: EIX-Insight Discovery to cut through the noise, automatically identify meaningful insights from high-volume, high-complexity data sources and support research, editorial and business intelligence functions. EIX-Boosting Audience Engagement to use advanced personalization and intelligent content tagging to deliver more relevant, resonant experiences across channels, driving engagement and measurable growth. EIX-Insight Repurposing to transform previously published content and internal knowledge into new, high-value content assets, streamlining editorial operations and amplifying return on existing data. These new solutions are part of the EidenAI Suite, Expert.ai's modular AI ecosystem designed to support industry-specific challenges in media, insurance, pharma and life sciences, banking, financial services and more. With built-in explainability, governance and seamless integration, EidenAI Suite empowers organizations to scale language-based intelligence with speed, safety and precision.お知らせ • Jul 03+ 1 more updateExpert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million.Expert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million on July 1, 2025. The price of the acquisition is approximately €4.8 million (equity value) and will be settled in multiple tranches, distributed over different time periods, some of which will be after the completion of the partial demerger of S&I, as detailed below. The transaction has been fully financed through the use of internal funds. Through this acquisition, expert.ai strengthens its position in Public Administration and Digital Healthcare sectors. The shareholders of ISED, seizing the opportunity for the Company's development, have also decided to reinvest part of the proceeds from the sale of ISED into Expert.ai (the “ISED Investors”), committing to subscribe to a tranche of the Capital Increase reserved for them. The following are ISED's latest financial figures for the financial statements as of December 31, 2024: revenues of €8.8 million; EBITDA of €1.0 million with an EBITDA margin of 11%. The Board of Directors of Expert.ai Approved and simultaneously finalized the acquisition of 100% of th share capital of ISED S.p.A. Lexia acted as legal advisor and Rossella Lehnus, Emanuele Rita, Edoardo Tamburelli, Laura Caucci Molara and Andrea Gagliardi of Deloitte Financial Advisory S.r.l. acted as Financial Advisor to the Company. Scacchi Law Firm acted as legal advisor and ncesco Martinelli of Studio Martinelli acted as Financial Advisor to seller. The Caruso Andreatini Notai Associati firm , together with the lawyer Gabriella Pizzi , took care of the notarial profiles. Expert.ai S.p.A. (BIT:EXAI) completed the acquisition of I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. on July 1, 2025.お知らせ • May 13Expert.ai S.p.A., Annual General Meeting, May 27, 2025Expert.ai S.p.A., Annual General Meeting, May 27, 2025, at 15:00 W. Europe Standard Time.お知らせ • Apr 08Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A.Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A on April 7, 2025. The non-binding agreement provides for (i) the establishment of a newco by Tiscali (the ‘NewCo’); (ii) the transfer of the Villanova Project to NewCo, and (iii) the subsequent investment by expert.ai in NewCo. Upon completion of the Transaction, it is expected that expert.ai will hold a stake equal to not less than 40% of NewCo's share capital. The Non-Binding Agreement provides for Tiscali's commitment, until June 30, 2025 unless expert.ai informs Tiscali that it does not wish to proceed with the Transaction not to engage in negotiations or discussions concerning the Project with parties other than expert.ai. The Transaction is contingent on the granting of any necessary authorizations by all relevant authorities and public bodies (including, but not limited to, the European Commission and MimiT) as well as the finalization of binding agreements.お知らせ • Feb 01+ 1 more updateExpert.ai S.p.A. to Report First Half, 2025 Results on Sep 30, 2025Expert.ai S.p.A. announced that they will report first half, 2025 results on Sep 30, 2025お知らせ • Jul 27Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million.Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,761,008 Price\Range: €1.1 Transaction Features: Rights Offeringお知らせ • May 31Expert.ai S.p.A. announced that it expects to receive €1.2 million in fundingExpert.ai S.p.A. announced a private placement to issue common shares for the gross proceeds of €1,200,000 on May 30, 2024.お知らせ • Apr 16Expert.ai Launches Insight Engine for Life SciencesExpert.ai announced the launch of the expert.ai Insight Engine for Life Sciences. For the world of drug research and development, data is both a challenge to be managed and an opportunity to be leveraged. The ability to effectively and quickly mine scientific and biomedical content for developing new drugs and to design and operate clinical trials is more critical than ever before. The complexity of the diverse data sources that researchers depend on makes integrating, standardizing and analyzing them both challenging and time consuming. Commercial licensing and data access restrictions, as well as the lack of granularity and different taxonomies used by common search tools, further complicate the process. The convergence of these challenges in this fast-paced field impacts clinical research and delays drug development efforts, and it's precisely here that advanced AI technologies are adding significant value. Expert.ai Insight Engine for Life Sciences supports multiple use cases, including: Competitive Intelligence: Provide direct access to ongoing trials filtered for any combination of drug, indication, mechanism of action, sponsor or geography. Zoom into particular areas on the fly to gauge the competition's pipelines. Connect with both public and private research articles, research findings and emerging trends. Clinical Trial Design Optimization: Support clinical operations in optimizing the design and planning of a trial by identifying similar trials, comparing protocols, identifying suitable sites and patient populations, or assessing success criteria. This helps improve recruitment, allowing teams to compare design complexity based on inclusion/exclusion criteria and mine schedule of assessment data in protocol documents for site and patient burden assessments. Intellectual Property Protection: Automatically review patent claims against published papers and clinical trial activity, reducing the time that IP professionals spend on administrative activities and all IP-related tasks. Research Intelligence: Help researchers quickly access and analyze a vast amount of relevant information coming from biomedical and scientific literature, including full texts, speeding up the discovery and development of new drugs and therapies. As one of the finalists of the Bio-IT World"Best of Show" Awards, expert.ai will be showcasing its Insight Engine for Life Sciences at the Bio-IT World Conference & Expo in Boston (April 15-17, 2024), where a team of expert judges will view entries on site and choose winners based on the product's technical merit, functionality, innovation and in-person presentations.お知らせ • Apr 11Expert.ai S.p.A. to Report Fiscal Year 2023 Results on Apr 24, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Apr 24, 2024お知らせ • Dec 13+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2023 Results on Mar 28, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Mar 28, 2024お知らせ • Jul 08Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023.お知らせ • Jan 31+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2022 Results on Mar 30, 2023Expert.ai S.p.A. announced that they will report fiscal year 2022 results on Mar 30, 2023財務状況分析短期負債: EXSP.Fの 短期資産 ( €37.1M ) が 短期負債 ( €21.0M ) を超えています。長期負債: EXSP.Fの短期資産 ( €37.1M ) が 長期負債 ( €21.3M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: EXSP.Fの 純負債対資本比率 ( 11.2% ) は 満足できる 水準であると考えられます。負債の削減: EXSP.Fの負債対資本比率は、過去 5 年間で132.1%から65.4%に減少しました。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 EXSP.Fに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: EXSP.Fの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YSoftware 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/13 10:31終値2026/02/13 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Expert.ai S.p.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Luca ArenaAlantra Capital Markets ResearchKatherine ThompsonEdison Investment ResearchDaniele AlibrandiStifel, Equities Research5 その他のアナリストを表示
お知らせ • Jan 30+ 1 more updateExpert.ai S.p.A. to Report First Half, 2026 Results on Sep 28, 2026Expert.ai S.p.A. announced that they will report first half, 2026 results on Sep 28, 2026
お知らせ • Nov 26Expert.ai Presents EIX-Customer Screening for Intelligent Adverse News Monitoring in the Financial SectorExpert.ai released its enhanced solution for helping banks and financial institutions continuously monitor and analyze media coverage related to potential criminal activity or investigations involving customers. Available through the EidenAI Suite, Expert.ai's ecosystem of AI tools and solutions designed for industry, EIX-Customer Screening leverages advanced technologies to reinforce anti-money laundering (AML) programs and help organizations adopt a more proactive Know Your Customer (KYC) approach. With financial crime on the rise and regulatory requirements becoming increasingly stringent, EIX- Customer Screening automates the monitoring and analysis of news related to customers and counterparties--in real time and on a global scale. The solution significantly reduces false positives, streamlines oversight activities and improves operational efficiency. Powered by a Hybrid AI approach that combines cutting-edge capabilities, EIX-Customer Screened processes large volumes of multilingual news and unstructured data to help teams quickly detect critical events and adverse media, such as criminal activity, investigations or legal proceedings while drastically reducing false positives. The solution also supports sanctions screening and identification of politically exposed persons (PEPs), enhancing compliance and due diligence workflows for better accuracy and security. EIX-Customer Screening sets a new standard for AML and KYC programs. Built on Expert.ai's extensive technological expertise, deep domain knowledge and years of experience serving leading banking and financial organizations, the solution offers enhanced support for analysts by enabling: Continuous monitoring and analysis of global information flows (news, corporate records, regulatory lists, etc.) to deliver a complete, 360deg view of customer risk; Intelligent detection and classification across 60+ crime categories; Extraction of contextual data (e.g., age, role, location of individuals involved); Customizable relevance and risk scoring with up to 90% reduction in false positives, enabling teams to focus on true risks and accelerate AML investigations and customer onboarding; Screening against major global sanctions lists (UN, EU, OFAC, etc.) and PEP Checks and automatic generation of reports, alerts and summaries for AML/KYC teams. EIX-Customer Screened supports both large institutions and small organizations, making it easy to scale monitoring across the entire customer portfolio or targeted segments. The solution is available and integrates seamlessly with leading compliance platforms.
お知らせ • Oct 15Expert.ai Strengthens Its Offering for the Insurance Industry with Advanced AI SolutionsExpert.ai announced significant enhancements to its insurance solutions available through the EidenAI Suite. The updates further strengthen Expert.ai's position as the trusted AI partner for insurers, MGAs, brokers and TPAs, delivering measurable value across core insurance functions and helping organizations accelerate processes, reduce risk and enable scalability across operations. The improved offering includes three specialized solutions that deliver measurable value across core insurance functions. All are available as turnkey and highly customized deployments with built-in governance and monitoring capabilities to ensure safe, transparent and compliant adoption of AI: AI-Powered Underwriting: Accuracy and speed in underwriting are essential for competitive advantage. EIX-Underwriting leverages its proven Hybrid AI approach to streamline data extraction from unstructured documents and risk evaluation, ensuring scalable performance even during peak demand periods. All commercial lines, both admitted and E&S, are supported. Claims Automation: Designed to eliminate bottlenecks in high-volume, document-intensive claims environments, Expert.ai's EIX-Claims Automation solution intelligently classifies and extracts critical data from incoming documents, speeding resolutions, reducing leakage, and improving customer satisfaction. The solution includes legal demand identification and medical summarization. Policy Servicing Automation: Outdated servicing processes often slow operations and create low customer satisfaction. Through EIX-Policy Servicing, Expert.ai helps teams automate workflows, such as endorsement, audit and renewal processing, end-to-end, while enhancing compliance, reducing operational costs and improving service delivery with intelligent, auditable processes.
お知らせ • Oct 07Expert.ai Introduces New AI Solutions to Accelerate Pharma & Life Sciences InnovationExpert.ai announced the debut of its new AI-powered offerings designed to accelerate innovation across the pharmaceutical, healthcare and life sciences industries. Launched at BioTechX Europe 2025, Europe's largest congress dedicated to pharma & healthcare, the new solutions enable organizations to enhance data analysis, streamline discovery processes and unlock new possibilities for clinical trials and therapeutic improvement: EIX-Submission Readiness empowers teams to build smarter, more efficient workflows for regulatory documentation. EIX-Preclinical Document Intelligence streamlines preclinical documentation with greater speed and accuracy, free experts to focus on innovation. EIX-Clinical Trials Intelligence helps research teams to distill the most accurate, up-to-date information by disrupting across mountains of content from clinical registries, scientific publications and real-world data. EIX-IP Detection delivers comprehensive, explainable insights across patents, scientific literature and clinical trial data. Leveraging its deep domain expertise and unique hybrid AI approach, Expert.ai helps researchers transform the complexity of research & development into strategic advantage. By reducing manual effort and scaling insights from massive volumes of data, the new solutions use the most effective AI techniques to ensure regulatory accuracy, improve trial design, accelerate patient recruitment, reduce costs and minimize the constant risks of delays. With these innovations, Expert.ai continues to set the standard for applying AI in Pharma & Life Sciences, delivering greater efficiency and reliability across the life sciences value chain through intelligent document automation and AI agents.
お知らせ • Sep 12Expert.Ai Launches Enhanced Solutions for Digital Information ServicesExpert.ai presents enhanced AI-powered solutions purpose-built for Digital Information Services. In data-saturated landscape, information services organizations must quickly convert vast, diverse streams of both structured and unstructured information into clear, actionable insights. Expert.ai empowers this transformation through advanced Hybrid AI capabilities that automate classification, entity and relationship extraction, tagging and semantic enrichment, similarity detection, and personalized recommendations. By extending content usability, Expert.ai maximizes the value of data, simplifying its governance and supporting continuous innovation through the best of diverse AI techniques -- including neuro-symbolic AI, AI agents, LLMs and the broader Generative AI ecosystem -- all tailored to extract meaning from complexity. Transforming how information services teams operate, Expert.ai streamlines workflows, enabling professionals to focus on high-value tasks, accelerate insight generation and repurpose knowledge across domains. New Expert.ai solutions for Digital Information Services include: EIX-Insight Discovery to cut through the noise, automatically identify meaningful insights from high-volume, high-complexity data sources and support research, editorial and business intelligence functions. EIX-Boosting Audience Engagement to use advanced personalization and intelligent content tagging to deliver more relevant, resonant experiences across channels, driving engagement and measurable growth. EIX-Insight Repurposing to transform previously published content and internal knowledge into new, high-value content assets, streamlining editorial operations and amplifying return on existing data. These new solutions are part of the EidenAI Suite, Expert.ai's modular AI ecosystem designed to support industry-specific challenges in media, insurance, pharma and life sciences, banking, financial services and more. With built-in explainability, governance and seamless integration, EidenAI Suite empowers organizations to scale language-based intelligence with speed, safety and precision.
お知らせ • Jul 03+ 1 more updateExpert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million.Expert.ai S.p.A. (BIT:EXAI) acquired I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. for €4.8 million on July 1, 2025. The price of the acquisition is approximately €4.8 million (equity value) and will be settled in multiple tranches, distributed over different time periods, some of which will be after the completion of the partial demerger of S&I, as detailed below. The transaction has been fully financed through the use of internal funds. Through this acquisition, expert.ai strengthens its position in Public Administration and Digital Healthcare sectors. The shareholders of ISED, seizing the opportunity for the Company's development, have also decided to reinvest part of the proceeds from the sale of ISED into Expert.ai (the “ISED Investors”), committing to subscribe to a tranche of the Capital Increase reserved for them. The following are ISED's latest financial figures for the financial statements as of December 31, 2024: revenues of €8.8 million; EBITDA of €1.0 million with an EBITDA margin of 11%. The Board of Directors of Expert.ai Approved and simultaneously finalized the acquisition of 100% of th share capital of ISED S.p.A. Lexia acted as legal advisor and Rossella Lehnus, Emanuele Rita, Edoardo Tamburelli, Laura Caucci Molara and Andrea Gagliardi of Deloitte Financial Advisory S.r.l. acted as Financial Advisor to the Company. Scacchi Law Firm acted as legal advisor and ncesco Martinelli of Studio Martinelli acted as Financial Advisor to seller. The Caruso Andreatini Notai Associati firm , together with the lawyer Gabriella Pizzi , took care of the notarial profiles. Expert.ai S.p.A. (BIT:EXAI) completed the acquisition of I.S.E.D. Ingegneria Dei Sistemi Elaborazione Dati Spa from S.& I. - Servizi Per L'Innovazione - S.R.L. Piu' Brevemente S.& I. - S.R.L. on July 1, 2025.
お知らせ • May 13Expert.ai S.p.A., Annual General Meeting, May 27, 2025Expert.ai S.p.A., Annual General Meeting, May 27, 2025, at 15:00 W. Europe Standard Time.
お知らせ • Apr 08Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A.Expert.ai S.p.A. (BIT:EXAI) entered into a non-binding agreement to acquire 40% stake in Villanova Project from Tiscali Italia S.p.A on April 7, 2025. The non-binding agreement provides for (i) the establishment of a newco by Tiscali (the ‘NewCo’); (ii) the transfer of the Villanova Project to NewCo, and (iii) the subsequent investment by expert.ai in NewCo. Upon completion of the Transaction, it is expected that expert.ai will hold a stake equal to not less than 40% of NewCo's share capital. The Non-Binding Agreement provides for Tiscali's commitment, until June 30, 2025 unless expert.ai informs Tiscali that it does not wish to proceed with the Transaction not to engage in negotiations or discussions concerning the Project with parties other than expert.ai. The Transaction is contingent on the granting of any necessary authorizations by all relevant authorities and public bodies (including, but not limited to, the European Commission and MimiT) as well as the finalization of binding agreements.
お知らせ • Feb 01+ 1 more updateExpert.ai S.p.A. to Report First Half, 2025 Results on Sep 30, 2025Expert.ai S.p.A. announced that they will report first half, 2025 results on Sep 30, 2025
お知らせ • Jul 27Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million.Expert.ai S.p.A. has completed a Follow-on Equity Offering in the amount of €26.137109 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,761,008 Price\Range: €1.1 Transaction Features: Rights Offering
お知らせ • May 31Expert.ai S.p.A. announced that it expects to receive €1.2 million in fundingExpert.ai S.p.A. announced a private placement to issue common shares for the gross proceeds of €1,200,000 on May 30, 2024.
お知らせ • Apr 16Expert.ai Launches Insight Engine for Life SciencesExpert.ai announced the launch of the expert.ai Insight Engine for Life Sciences. For the world of drug research and development, data is both a challenge to be managed and an opportunity to be leveraged. The ability to effectively and quickly mine scientific and biomedical content for developing new drugs and to design and operate clinical trials is more critical than ever before. The complexity of the diverse data sources that researchers depend on makes integrating, standardizing and analyzing them both challenging and time consuming. Commercial licensing and data access restrictions, as well as the lack of granularity and different taxonomies used by common search tools, further complicate the process. The convergence of these challenges in this fast-paced field impacts clinical research and delays drug development efforts, and it's precisely here that advanced AI technologies are adding significant value. Expert.ai Insight Engine for Life Sciences supports multiple use cases, including: Competitive Intelligence: Provide direct access to ongoing trials filtered for any combination of drug, indication, mechanism of action, sponsor or geography. Zoom into particular areas on the fly to gauge the competition's pipelines. Connect with both public and private research articles, research findings and emerging trends. Clinical Trial Design Optimization: Support clinical operations in optimizing the design and planning of a trial by identifying similar trials, comparing protocols, identifying suitable sites and patient populations, or assessing success criteria. This helps improve recruitment, allowing teams to compare design complexity based on inclusion/exclusion criteria and mine schedule of assessment data in protocol documents for site and patient burden assessments. Intellectual Property Protection: Automatically review patent claims against published papers and clinical trial activity, reducing the time that IP professionals spend on administrative activities and all IP-related tasks. Research Intelligence: Help researchers quickly access and analyze a vast amount of relevant information coming from biomedical and scientific literature, including full texts, speeding up the discovery and development of new drugs and therapies. As one of the finalists of the Bio-IT World"Best of Show" Awards, expert.ai will be showcasing its Insight Engine for Life Sciences at the Bio-IT World Conference & Expo in Boston (April 15-17, 2024), where a team of expert judges will view entries on site and choose winners based on the product's technical merit, functionality, innovation and in-person presentations.
お知らせ • Apr 11Expert.ai S.p.A. to Report Fiscal Year 2023 Results on Apr 24, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Apr 24, 2024
お知らせ • Dec 13+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2023 Results on Mar 28, 2024Expert.ai S.p.A. announced that they will report fiscal year 2023 results on Mar 28, 2024
お知らせ • Jul 08Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023Expert.ai S.p.A., Annual General Meeting, Jul 24, 2023.
お知らせ • Jan 31+ 2 more updatesExpert.ai S.p.A. to Report Fiscal Year 2022 Results on Mar 30, 2023Expert.ai S.p.A. announced that they will report fiscal year 2022 results on Mar 30, 2023